Women with Mild Fasting Hyperglycemia in Early Pregnancy Have More Neonatal Intensive Care Admissions

J Clin Endocrinol Metab. 2021 Jan 23;106(2):e836-e854. doi: 10.1210/clinem/dgaa831.

Abstract

Aims: To determine impact of mild fasting hyperglycemia in early pregnancy (fasting plasma glucose [FPG] 5.1-5.5 mmol/L) on pregnancy outcomes.

Methods: We measured FPG at 11.9 ± 1.8 weeks in 2006 women from a prospective cohort study. Women with FPG ≥5.6 mmol/L (19) received treatment and were excluded from further analyses. A total of 1838 women with FPG <5.6 mmol/L received a 75 g oral glucose tolerance test (OGTT) between 24 and 28 weeks of pregnancy.

Results: Of all participants, 78 (4.2%) had FPG 5.1 to 5.5 mmol/L in early pregnancy, of which 49 had a normal OGTT later in pregnancy (high fasting normal glucose tolerance [NGT] group). Compared with the NGT group with FPG <5.1 mmol/L in early pregnancy (low fasting NGT group, n = 1560), the high fasting NGT group had a higher body mass index (BMI), higher insulin resistance with more impaired insulin secretion and higher FPG and 30 minute glucose levels on the OGTT. The admission rate to neonatal intensive care unit (NICU) was significantly higher in the high fasting NGT group than in the low fasting NGT group (20.4% [10] vs 9.3% [143], P = .009), with no difference in duration (7.0 ± 8.6 vs 8.4 ± 14.3 days, P = .849) or indication for NICU admission between both groups. The admission rate to NICU remained significantly higher (odds ratio 2.47; 95% confidence interval 1.18-5.19, P = .017) after adjustment for age, BMI, and glucose levels at the OGTT.

Conclusions: When provision of an OGTT is limited such as in the Covid-19 pandemic, using FPG in early pregnancy could be an easy alternative to determine who is at increased risk for adverse pregnancy outcomes.

Keywords: 2013 WHO criteria; early pregnancy; gestational diabetes mellitus; pregnancy outcomes.

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • COVID-19
  • Fasting / blood*
  • Female
  • Gestational Age
  • Glucose Tolerance Test
  • Humans
  • Hyperglycemia / blood*
  • Hyperglycemia / diagnosis
  • Hyperglycemia / epidemiology
  • Infant, Newborn
  • Infant, Newborn, Diseases / epidemiology
  • Infant, Newborn, Diseases / etiology
  • Infant, Newborn, Diseases / therapy
  • Intensive Care, Neonatal / statistics & numerical data*
  • Pandemics
  • Patient Admission / statistics & numerical data*
  • Pregnancy
  • Pregnancy Complications / blood*
  • Pregnancy Complications / diagnosis
  • Pregnancy Complications / epidemiology
  • Pregnancy Outcome / epidemiology
  • Prenatal Exposure Delayed Effects / blood
  • Prenatal Exposure Delayed Effects / epidemiology
  • Prenatal Exposure Delayed Effects / therapy
  • Prospective Studies
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index
  • Young Adult

Substances

  • Blood Glucose